Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need.

Infectious diseases and therapy

Bidell MR, McLaughlin M, Faragon J, Morse C, Patel N.
PMID: 27384319
Infect Dis Ther. 2016 Sep;5(3):299-312. doi: 10.1007/s40121-016-0118-x. Epub 2016 Jul 06.

There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection. This is largely due to the approval of several direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms of action. These...

Cite
Bidell MR, McLaughlin M, Faragon J, et al. Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. Infect Dis Ther. 2016;5(3):299-312doi: 10.1007/s40121-016-0118-x.
Bidell, M. R., McLaughlin, M., Faragon, J., Morse, C., & Patel, N. (2016). Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. Infectious diseases and therapy, 5(3), 299-312. https://doi.org/10.1007/s40121-016-0118-x
Bidell, Monique R, et al. "Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need." Infectious diseases and therapy vol. 5,3 (2016): 299-312. doi: https://doi.org/10.1007/s40121-016-0118-x
Bidell MR, McLaughlin M, Faragon J, Morse C, Patel N. Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. Infect Dis Ther. 2016 Sep;5(3):299-312. doi: 10.1007/s40121-016-0118-x. Epub 2016 Jul 06. PMID: 27384319; PMCID: PMC5019974.
Copy Download .nbib Format: NLM
Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study.

Infectious diseases and therapy

McConnell HL, Perris ET, Lowry C, Lodise T, Patel N.
PMID: 25245515
Infect Dis Ther. 2014 Dec;3(2):225-33. doi: 10.1007/s40121-014-0041-y. Epub 2014 Sep 23.

INTRODUCTION: The prescribing information for daptomycin recommends discontinuing statin therapy during receipt of daptomycin. The literature supporting this recommendation is sparse. The objectives of this study were to examine the impact of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) on creatine...

Cite
McConnell HL, Perris ET, Lowry C, et al. Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study. Infect Dis Ther. 2014;3(2):225-33doi: 10.1007/s40121-014-0041-y.
McConnell, H. L., Perris, E. T., Lowry, C., Lodise, T., & Patel, N. (2014). Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study. Infectious diseases and therapy, 3(2), 225-33. https://doi.org/10.1007/s40121-014-0041-y
McConnell, Heather L, et al. "Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study." Infectious diseases and therapy vol. 3,2 (2014): 225-33. doi: https://doi.org/10.1007/s40121-014-0041-y
McConnell HL, Perris ET, Lowry C, Lodise T, Patel N. Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study. Infect Dis Ther. 2014 Dec;3(2):225-33. doi: 10.1007/s40121-014-0041-y. Epub 2014 Sep 23. PMID: 25245515; PMCID: PMC4269631.
Copy Download .nbib Format: NLM
Biodiversity and apomixis: Insights from the East-Asian holly ferns in Polystichum section Xiphopolystichum.

Molecular phylogenetics and evolution

Patel N, Li CX, Zhang LB, Barrington DS.
PMID: 29763663
Mol Phylogenet Evol. 2018 Oct;127:345-355. doi: 10.1016/j.ympev.2018.05.003. Epub 2018 May 12.

No abstract available.

Cite
Patel N, Li CX, Zhang LB, et al. Biodiversity and apomixis: Insights from the East-Asian holly ferns in Polystichum section Xiphopolystichum. Mol Phylogenet Evol. 2018;127:345-355doi: 10.1016/j.ympev.2018.05.003.
Patel, N., Li, C. X., Zhang, L. B., & Barrington, D. S. (2018). Biodiversity and apomixis: Insights from the East-Asian holly ferns in Polystichum section Xiphopolystichum. Molecular phylogenetics and evolution, 127345-355. https://doi.org/10.1016/j.ympev.2018.05.003
Patel, Nikisha, et al. "Biodiversity and apomixis: Insights from the East-Asian holly ferns in Polystichum section Xiphopolystichum." Molecular phylogenetics and evolution vol. 127 (2018): 345-355. doi: https://doi.org/10.1016/j.ympev.2018.05.003
Patel N, Li CX, Zhang LB, Barrington DS. Biodiversity and apomixis: Insights from the East-Asian holly ferns in Polystichum section Xiphopolystichum. Mol Phylogenet Evol. 2018 Oct;127:345-355. doi: 10.1016/j.ympev.2018.05.003. Epub 2018 May 12. PMID: 29763663.
Copy Download .nbib Format: NLM
Prevalence and Predictors of Important Telaprevir Drug Interactions Among Patients Coinfected With Hepatitis C and Human Immunodeficiency Virus.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Patel N, Veve M, Bliss S, Nasiri M, McNutt LA, Lazariu V, Roman M, Miller C.
PMID: 34860905
J Pharm Technol. 2014 Oct;30(5):159-167. doi: 10.1177/8755122514533941. Epub 2014 May 02.

No abstract available.

Cite
Patel N, Veve M, Bliss S, et al. Prevalence and Predictors of Important Telaprevir Drug Interactions Among Patients Coinfected With Hepatitis C and Human Immunodeficiency Virus. J Pharm Technol. 2014;30(5):159-167doi: 10.1177/8755122514533941.
Patel, N., Veve, M., Bliss, S., Nasiri, M., McNutt, L. A., Lazariu, V., Roman, M., & Miller, C. (2014). Prevalence and Predictors of Important Telaprevir Drug Interactions Among Patients Coinfected With Hepatitis C and Human Immunodeficiency Virus. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 30(5), 159-167. https://doi.org/10.1177/8755122514533941
Patel, Nimish, et al. "Prevalence and Predictors of Important Telaprevir Drug Interactions Among Patients Coinfected With Hepatitis C and Human Immunodeficiency Virus." The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians vol. 30,5 (2014): 159-167. doi: https://doi.org/10.1177/8755122514533941
Patel N, Veve M, Bliss S, Nasiri M, McNutt LA, Lazariu V, Roman M, Miller C. Prevalence and Predictors of Important Telaprevir Drug Interactions Among Patients Coinfected With Hepatitis C and Human Immunodeficiency Virus. J Pharm Technol. 2014 Oct;30(5):159-167. doi: 10.1177/8755122514533941. Epub 2014 May 02. PMID: 34860905; PMCID: PMC5990149.
Copy Download .nbib Format: NLM
New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.

HIV/AIDS (Auckland, N.Z.)

Patel N, Miller CD.
PMID: 22570576
HIV AIDS (Auckl). 2012;4:61-71. doi: 10.2147/HIV.S25149. Epub 2012 Apr 27.

Fixed-dose combination tablets have become an important therapy option for patients infected with the human immunodeficiency virus. Fixed-dose combination rilpivirine-tenofovir-emtricitabine is a recently approved therapy option that has been extensively studied within the treatment-naïve population. When compared with efavirenz-based...

Cite
Patel N, Miller CD. New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir. HIV AIDS (Auckl). 2012;4:61-71doi: 10.2147/HIV.S25149.
Patel, N., & Miller, C. D. (2012). New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir. HIV/AIDS (Auckland, N.Z.), 461-71. https://doi.org/10.2147/HIV.S25149
Patel, Nimish, and Miller, Christopher D. "New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir." HIV/AIDS (Auckland, N.Z.) vol. 4 (2012): 61-71. doi: https://doi.org/10.2147/HIV.S25149
Patel N, Miller CD. New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir. HIV AIDS (Auckl). 2012;4:61-71. doi: 10.2147/HIV.S25149. Epub 2012 Apr 27. PMID: 22570576; PMCID: PMC3346062.
Copy Download .nbib Format: NLM
US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales.

Open forum infectious diseases

Lodise TP, Henriksen AS, Hadley T, Patel N.
PMID: 34660834
Open Forum Infect Dis. 2021 Oct 15;8(10):ofab380. doi: 10.1093/ofid/ofab380. eCollection 2021 Oct.

BACKGROUND: Pivmecillinam is approved for the treatment of adults with uncomplicated urinary tract infection (uUTI) in Canada and Europe and is pending United States (US) Food and Drug Administration submission for consideration for approval. US-focused health care decision-analytics were...

Cite
Lodise TP, Henriksen AS, Hadley T, et al. US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales. Open Forum Infect Dis. 2021;8(10):ofab380doi: 10.1093/ofid/ofab380.
Lodise, T. P., Henriksen, A. S., Hadley, T., & Patel, N. (2021). US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales. Open forum infectious diseases, 8(10), ofab380. https://doi.org/10.1093/ofid/ofab380
Lodise, Thomas P, et al. "US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales." Open forum infectious diseases vol. 8,10 (2021): ofab380. doi: https://doi.org/10.1093/ofid/ofab380
Lodise TP, Henriksen AS, Hadley T, Patel N. US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales. Open Forum Infect Dis. 2021 Oct 15;8(10):ofab380. doi: 10.1093/ofid/ofab380. eCollection 2021 Oct. PMID: 34660834; PMCID: PMC8516593.
Copy Download .nbib Format: NLM
Overcoming Past Perceptions and Profession-Wide Identity Crisis to Reflect Pharmacy's Future.

American journal of pharmaceutical education

Wagner JL, Boyle J, Boyle CJ, Choi D, Ballou JM, Patel N, Persky AM, Malcom DR.
PMID: 34785501
Am J Pharm Educ. 2021 Nov 16;8829. doi: 10.5688/ajpe8829. Epub 2021 Nov 16.

The profession of pharmacy has come to encompass a myriad of identities including apothecary, dispenser, merchandiser, expert advisor, and health care provider. While these have changed over time, the responsibilities and scope of practice have not evolved to keep...

Cite
Wagner JL, Boyle J, Boyle CJ, et al. Overcoming Past Perceptions and Profession-Wide Identity Crisis to Reflect Pharmacy's Future. Am J Pharm Educ. 2021;8829doi: 10.5688/ajpe8829.
Wagner, J. L., Boyle, J., Boyle, C. J., Choi, D., Ballou, J. M., Patel, N., Persky, A. M., & Malcom, D. R. (2021). Overcoming Past Perceptions and Profession-Wide Identity Crisis to Reflect Pharmacy's Future. American journal of pharmaceutical education, 8829. https://doi.org/10.5688/ajpe8829
Wagner, Jamie L, et al. "Overcoming Past Perceptions and Profession-Wide Identity Crisis to Reflect Pharmacy's Future." American journal of pharmaceutical education vol. (2021): 8829. doi: https://doi.org/10.5688/ajpe8829
Wagner JL, Boyle J, Boyle CJ, Choi D, Ballou JM, Patel N, Persky AM, Malcom DR. Overcoming Past Perceptions and Profession-Wide Identity Crisis to Reflect Pharmacy's Future. Am J Pharm Educ. 2021 Nov 16;8829. doi: 10.5688/ajpe8829. Epub 2021 Nov 16. PMID: 34785501.
Copy Download .nbib Format: NLM
A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients.

Infectious diseases and therapy

Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, Miller C.
PMID: 25708155
Infect Dis Ther. 2015 Jan 28; doi: 10.1007/s40121-015-0058-x. Epub 2015 Jan 28.

INTRODUCTION: This study compares the expected occurrence of contraindicated drug-drug interactions (XDDIs) when simeprevir (SIM)- or sofosbuvir (SOF)-containing therapy is added to medication profiles of patients with hepatitis C (HCV) monoinfection to quantify, in relative terms, the population-based risk...

Cite
Patel N, Nasiri M, Koroglu A, et al. A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients. Infect Dis Ther. 2015;doi: 10.1007/s40121-015-0058-x.
Patel, N., Nasiri, M., Koroglu, A., Bliss, S., Davis, M., McNutt, L. A., & Miller, C. (2015). A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients. Infectious diseases and therapy, . https://doi.org/10.1007/s40121-015-0058-x
Patel, Nimish, et al. "A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients." Infectious diseases and therapy vol. (2015). doi: https://doi.org/10.1007/s40121-015-0058-x
Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, Miller C. A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients. Infect Dis Ther. 2015 Jan 28; doi: 10.1007/s40121-015-0058-x. Epub 2015 Jan 28. PMID: 25708155; PMCID: PMC4363220.
Copy Download .nbib Format: NLM
A target enrichment probe set for resolving the flagellate land plant tree of life.

Applications in plant sciences

Breinholt JW, Carey SB, Tiley GP, Davis EC, Endara L, McDaniel SF, Neves LG, Sessa EB, von Konrat M, Chantanaorrapint S, Fawcett S, Ickert-Bond SM, Labiak PH, Larraín J, Lehnert M, Lewis LR, Nagalingum NS, Patel N, Rensing SA, Testo W, Vasco A, Villarreal JC, Williams EW, Burleigh JG.
PMID: 33552748
Appl Plant Sci. 2021 Jan 24;9(1):e11406. doi: 10.1002/aps3.11406. eCollection 2021 Jan.

PREMISE: New sequencing technologies facilitate the generation of large-scale molecular data sets for constructing the plant tree of life. We describe a new probe set for target enrichment sequencing to generate nuclear sequence data to build phylogenetic trees with...

Cite
Breinholt JW, Carey SB, Tiley GP, et al. A target enrichment probe set for resolving the flagellate land plant tree of life. Appl Plant Sci. 2021;9(1):e11406doi: 10.1002/aps3.11406.
Breinholt, J. W., Carey, S. B., Tiley, G. P., Davis, E. C., Endara, L., McDaniel, S. F., Neves, L. G., Sessa, E. B., von Konrat, M., Chantanaorrapint, S., Fawcett, S., Ickert-Bond, S. M., Labiak, P. H., Larraín, J., Lehnert, M., Lewis, L. R., Nagalingum, N. S., Patel, N., Rensing, S. A., Testo, W., Vasco, A., Villarreal, J. C., Williams, E. W., & Burleigh, J. G. (2021). A target enrichment probe set for resolving the flagellate land plant tree of life. Applications in plant sciences, 9(1), e11406. https://doi.org/10.1002/aps3.11406
Breinholt, Jesse W, et al. "A target enrichment probe set for resolving the flagellate land plant tree of life." Applications in plant sciences vol. 9,1 (2021): e11406. doi: https://doi.org/10.1002/aps3.11406
Breinholt JW, Carey SB, Tiley GP, Davis EC, Endara L, McDaniel SF, Neves LG, Sessa EB, von Konrat M, Chantanaorrapint S, Fawcett S, Ickert-Bond SM, Labiak PH, Larraín J, Lehnert M, Lewis LR, Nagalingum NS, Patel N, Rensing SA, Testo W, Vasco A, Villarreal JC, Williams EW, Burleigh JG. A target enrichment probe set for resolving the flagellate land plant tree of life. Appl Plant Sci. 2021 Jan 24;9(1):e11406. doi: 10.1002/aps3.11406. eCollection 2021 Jan. PMID: 33552748; PMCID: PMC7845764.
Copy Download .nbib Format: NLM
Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.

Journal of acquired immune deficiency syndromes (1999)

Salama E, Hill L, Patel N, Best BM, Momper JD.
PMID: 34285156
J Acquir Immune Defic Syndr. 2021 Dec 01;88(4):389-392. doi: 10.1097/QAI.0000000000002765.

BACKGROUND: Bictegravir coformulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination (BIC/FTC/TAF 50/200/25 mg) is recommended as an initial regimen in patients who are antiretroviral (ARV)-naïve or virologically suppressed on a stable ARV regimen. However, no real-world pharmacokinetic...

Cite
Salama E, Hill L, Patel N, et al. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV. J Acquir Immune Defic Syndr. 2021;88(4):389-392doi: 10.1097/QAI.0000000000002765.
Salama, E., Hill, L., Patel, N., Best, B. M., & Momper, J. D. (2021). Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV. Journal of acquired immune deficiency syndromes (1999), 88(4), 389-392. https://doi.org/10.1097/QAI.0000000000002765
Salama, Engie, et al. "Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV." Journal of acquired immune deficiency syndromes (1999) vol. 88,4 (2021): 389-392. doi: https://doi.org/10.1097/QAI.0000000000002765
Salama E, Hill L, Patel N, Best BM, Momper JD. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV. J Acquir Immune Defic Syndr. 2021 Dec 01;88(4):389-392. doi: 10.1097/QAI.0000000000002765. PMID: 34285156.
Copy Download .nbib Format: NLM
Investigating the Relationship between Ambulatory and Hospital Patient Experience Scores in a Neurosurgery Practice.

Healthcare (Basel, Switzerland)

Meyrat R, Vivian E, Shah J, Sridhar A, Hurst BB, Shoup C, Graham RB, Katzen S, Mitchell B, Oh M, Patel NH.
PMID: 34574927
Healthcare (Basel). 2021 Sep 03;9(9). doi: 10.3390/healthcare9091153.

Patient experience is critically important on both clinical and business levels to healthcare organizations, medical groups, and physician practices. We sought to understand whether a relationship exists between patient satisfaction scores in different settings for medical providers who practice...

Cite
Meyrat R, Vivian E, Shah J, et al. Investigating the Relationship between Ambulatory and Hospital Patient Experience Scores in a Neurosurgery Practice. Healthcare (Basel). 2021;9(9)doi: 10.3390/healthcare9091153.
Meyrat, R., Vivian, E., Shah, J., Sridhar, A., Hurst, B. B., Shoup, C., Graham, R. B., Katzen, S., Mitchell, B., Oh, M., & Patel, N. H. (2021). Investigating the Relationship between Ambulatory and Hospital Patient Experience Scores in a Neurosurgery Practice. Healthcare (Basel, Switzerland), 9(9), . https://doi.org/10.3390/healthcare9091153
Meyrat, Richard, et al. "Investigating the Relationship between Ambulatory and Hospital Patient Experience Scores in a Neurosurgery Practice." Healthcare (Basel, Switzerland) vol. 9,9 (2021). doi: https://doi.org/10.3390/healthcare9091153
Meyrat R, Vivian E, Shah J, Sridhar A, Hurst BB, Shoup C, Graham RB, Katzen S, Mitchell B, Oh M, Patel NH. Investigating the Relationship between Ambulatory and Hospital Patient Experience Scores in a Neurosurgery Practice. Healthcare (Basel). 2021 Sep 03;9(9). doi: 10.3390/healthcare9091153. PMID: 34574927; PMCID: PMC8469641.
Copy Download .nbib Format: NLM
Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for .

Antibiotics (Basel, Switzerland)

Lodise T, Rodriguez M, Chitra S, Wright K, Patel N.
PMID: 34680776
Antibiotics (Basel). 2021 Oct 01;10(10). doi: 10.3390/antibiotics10101195.

INTRODUCTION: Approximately 3% of hospitalized patients with community-acquired bacterial pneumonia (CABP) develop healthcare-associated METHODS: A deterministic healthcare-decision analytic model was developed. The model population was hospitalized adult CABP patients with a DRS ≥ 6 across US hospitals (100,000 patients)....

Cite
Lodise T, Rodriguez M, Chitra S, et al. Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for . Antibiotics (Basel). 2021;10(10)doi: 10.3390/antibiotics10101195.
Lodise, T., Rodriguez, M., Chitra, S., Wright, K., & Patel, N. (2021). Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for . Antibiotics (Basel, Switzerland), 10(10), . https://doi.org/10.3390/antibiotics10101195
Lodise, Thomas, et al. "Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for ." Antibiotics (Basel, Switzerland) vol. 10,10 (2021). doi: https://doi.org/10.3390/antibiotics10101195
Lodise T, Rodriguez M, Chitra S, Wright K, Patel N. Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for . Antibiotics (Basel). 2021 Oct 01;10(10). doi: 10.3390/antibiotics10101195. PMID: 34680776; PMCID: PMC8532985.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries